{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:30:06Z","timestamp":1793694606011,"version":"4.5.1"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"6","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470144"],"award-info":[{"award-number":["82470144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Relapsed or refractory central nervous system lymphoma (R\/R CNSL) has limited treatment options. This multicenter retrospective study enrolled 84 consecutive patients with R\/R CNSL [median age, 59 years; median of 2.5 prior lines of therapy; 53 primary CNSL (PCNSL) and 31 secondary CNSL (SCNSL)] to evaluate the efficacy and safety profiles of glofitamab therapy. For PCNSL, the objective response rate (ORR) was 88% and complete response rate (CRR) was 59% with glofitamab monotherapy (n = 32) and 100% and 81% with combination therapy (n = 21), respectively. For SCNSL, ORR and CRR were 88% and 75% with glofitamab monotherapy (n = 8) and 91% and 65% with combination therapy (n = 23). At 14.7 months of follow-up, median progression-free survival was 19.5 months for PCNSL and 13.5 months for SCNSL. Cytokine release syndrome occurred in 40% (all grades 1\u20132) of patients, and immune effector cell\u2013associated neurotoxicity syndrome occurred in 8%. Glofitamab-based therapy demonstrated substantial activity with manageable toxicity in this study, offering a promising treatment paradigm for patients with R\/R CNSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Effective therapies are urgently needed for R\/R CNSL. Glofitamab-based therapy demonstrated high response rates in PCNSL (ORR, 92%; CRR, 68%) and SCNSL (ORR, 90%; CRR, 68%) with manageable toxicity in 84 consecutive, heavily pretreated patients, establishing a promising treatment option for this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0128","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:50:06Z","timestamp":1786477806000},"page":"909-920","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7583-7097","authenticated-orcid":false,"given":"Ruixian","family":"Xing","sequence":"first","affiliation":[{"name":"1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-4532","authenticated-orcid":false,"given":"Apeng","family":"Yang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030e09f60","id-type":"ROR","asserted-by":"publisher"}],"name":"The First Affiliated Hospital of Fujian Medical University 2 Department of Hematology, , Fuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1500-7569","authenticated-orcid":false,"given":"Juan","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qh26a66","id-type":"ROR","asserted-by":"publisher"}],"name":"Sichuan Academy of Medical Sciences and Sichuan Provincial People\u2019s Hospital 3 Department of Hematology, , University of Electronic Science and Technology of China, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-914X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013e4n276","id-type":"ROR","asserted-by":"publisher"}],"name":"Beijing Tongren Hospital 4 Department of Hematology, , Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1982-7131","authenticated-orcid":false,"given":"Wei","family":"Guo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"publisher"}],"name":"The First Hospital of Jilin University 5 Department of Hematology, , Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3935-8862","authenticated-orcid":false,"given":"Qu","family":"Cui","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8428-7835","authenticated-orcid":false,"given":"Xiaoqiong","family":"Tang","sequence":"additional","affiliation":[{"name":"6Department of Hematology Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5375-543X","authenticated-orcid":false,"given":"Yuanyuan","family":"Ma","sequence":"additional","affiliation":[{"name":"7Senior Department of Hematology, The Fifth Medical Center of People\u2019s Liberation Army (PLA), General Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2777-9080","authenticated-orcid":false,"given":"Kai","family":"Hu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/013e4n276","id-type":"ROR","asserted-by":"publisher"}],"name":"Beijing Gobroad Hospital 8 Department of Lymphoma and Myeloma Research Center, , Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3865-9129","authenticated-orcid":false,"given":"Tianheng","family":"He","sequence":"additional","affiliation":[{"name":"9Lymphoma Unit, Peking University International Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3267-6078","authenticated-orcid":false,"given":"Danyang","family":"Wu","sequence":"additional","affiliation":[{"name":"10Department of Hematology, The First Hospital of China Medical University, Shenyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8049-077X","authenticated-orcid":false,"given":"Xiaofang","family":"Deng","sequence":"additional","affiliation":[{"name":"11Department of Hematologic Oncology, Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9767-7879","authenticated-orcid":false,"given":"Yajing","family":"Zhang","sequence":"additional","affiliation":[{"name":"12Innovative Medical Center for Oncology and Immunology, Beijing Gobroad Boren Hospital, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-5538","authenticated-orcid":false,"given":"Kaili","family":"Zhong","sequence":"additional","affiliation":[{"name":"13Department of Lymphoma, Beijing Shijitan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2298-8642","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gw3ra78","id-type":"ROR","asserted-by":"publisher"}],"name":"Chinese PLA General Hospital 14 Department of Bio-Therapeutic, The Fifth Medical Center, , Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3915-6403","authenticated-orcid":false,"given":"Yixian","family":"Guo","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7607-7202","authenticated-orcid":false,"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"16Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8979-682X","authenticated-orcid":false,"given":"Chan","family":"Long","sequence":"additional","affiliation":[{"name":"17Department of Hematology, The First People\u2019s Hospital of Huizhou City, Huizhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1082-4428","authenticated-orcid":false,"given":"Chongyang","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02erhaz63","id-type":"ROR","asserted-by":"publisher"}],"name":"Lanzhou University Second Hospital 18 Department of Hematology, , Lanzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4487-4930","authenticated-orcid":false,"given":"Xin","family":"Lu","sequence":"additional","affiliation":[{"name":"19Department of Hematology, Xingtai People\u2019s Hospital, Xingtai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2927-2794","authenticated-orcid":false,"given":"Fengmin","family":"Li","sequence":"additional","affiliation":[{"name":"20Department of Hematology, The First Hospital of Qinhuangdao, Qinhuangdao, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-2148","authenticated-orcid":false,"given":"Jiefei","family":"Bai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02jwb5s28","id-type":"ROR","asserted-by":"publisher"}],"name":"Beijing Hospital 21 Department of Hematology, , National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9516-9071","authenticated-orcid":false,"given":"Jun","family":"Qian","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9787-7707","authenticated-orcid":false,"given":"Xuefei","family":"Sun","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0888-520X","authenticated-orcid":false,"given":"Wenrong","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04gw3ra78","id-type":"ROR","asserted-by":"publisher"}],"name":"The Fifth Medical Center of Chinese PLA General Hospital 22 Department of Hematology, , Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-5051","authenticated-orcid":false,"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[{"name":"23Department of Lymphoma and Hematology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University\/Hunan Cancer Hospital, Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-0026","authenticated-orcid":false,"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0152hn881","id-type":"ROR","asserted-by":"publisher"}],"name":"Tianjin Medical University Cancer Institute and Hospital 24 Department of Lymphoma, , Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4066-9473","authenticated-orcid":false,"given":"Ou","family":"Bai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"publisher"}],"name":"The First Hospital of Jilin University 5 Department of Hematology, , Changchun, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2083-7663","authenticated-orcid":false,"given":"Xiaobing","family":"Huang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01qh26a66","id-type":"ROR","asserted-by":"publisher"}],"name":"Sichuan Academy of Medical Sciences and Sichuan Provincial People\u2019s Hospital 3 Department of Hematology, , University of Electronic Science and Technology of China, Chengdu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0558-3906","authenticated-orcid":false,"given":"Zhiyong","family":"Zeng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/030e09f60","id-type":"ROR","asserted-by":"publisher"}],"name":"The First Affiliated Hospital of Fujian Medical University 2 Department of Hematology, , Fuzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2416-7572","authenticated-orcid":false,"given":"Lin","family":"Fu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2026110303165454100_bib1","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1186\/s12885-022-09315-8","article-title":"Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis","volume":"22","author":"Puhakka","year":"2022","journal-title":"BMC Cancer"},{"key":"2026110303165454100_bib2","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s11864-022-01017-4","article-title":"Secondary central nervous system lymphoma: updates in treatment and prophylaxis strategies","volume":"23","author":"Orellana-Noia","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2026110303165454100_bib3","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"key":"2026110303165454100_bib4","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nrneurol.2013.83","article-title":"Diagnosis and treatment of primary CNS lymphoma","volume":"9","author":"Korfel","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"2026110303165454100_bib5","doi-asserted-by":"publisher","first-page":"e3313","DOI":"10.1002\/hon.3313","article-title":"Characterizing second line and beyond therapies for primary central nervous system lymphomas","volume":"42","author":"Primeaux","year":"2024","journal-title":"Hematol Oncol"},{"key":"2026110303165454100_bib6","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"2026110303165454100_bib7","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1007\/s11864-022-01016-5","article-title":"Treatment options for recurrent primary CNS lymphoma","volume":"23","author":"Kaulen","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"2026110303165454100_bib8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026110303165454100_bib9","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"2026110303165454100_bib10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"key":"2026110303165454100_bib11","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"key":"2026110303165454100_bib12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1080\/10428194.2025.2484365","article-title":"Glofitamab induces deep and rapid response in relapsed primary central nervous system lymphoma","volume":"66","author":"Wang","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"2026110303165454100_bib13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41408-026-01519-6","article-title":"Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma","volume":"16","author":"Chohan","year":"2026","journal-title":"Blood Cancer J"},{"key":"2026110303165454100_bib14","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/bloodadvances.2025019322","article-title":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma","volume":"10","author":"Neumann","year":"2026","journal-title":"Blood Adv"},{"key":"2026110303165454100_bib15","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-04-0159","article-title":"Treatment of relapsed central nervous system lymphoma with high-dose methotrexate","volume":"10","author":"Plotkin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026110303165454100_bib16","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.ejca.2004.03.008","article-title":"Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial","volume":"40","author":"Reni","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026110303165454100_bib17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00277-018-3564-6","article-title":"(R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study","volume":"98","author":"Collignon","year":"2019","journal-title":"Ann Hematol"},{"key":"2026110303165454100_bib18","doi-asserted-by":"publisher","first-page":"e70083","DOI":"10.1002\/cncr.70083","article-title":"Meta-analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma","volume":"131","author":"Tan","year":"2025","journal-title":"Cancer"},{"key":"2026110303165454100_bib19","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","article-title":"Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"key":"2026110303165454100_bib20","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1182\/blood.2025029117","article-title":"Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab","volume":"146","author":"Brooks","year":"2025","journal-title":"Blood"},{"key":"2026110303165454100_bib21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"9","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"2026110303165454100_bib22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026110303165454100_bib23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.4161\/mabs.3.2.14239","article-title":"Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier","volume":"3","author":"Lampson","year":"2011","journal-title":"MAbs"},{"key":"2026110303165454100_bib24","doi-asserted-by":"publisher","first-page":"e1500108","DOI":"10.1080\/2162402X.2018.1500108","article-title":"Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system","volume":"7","author":"Maxwell","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026110303165454100_bib25","doi-asserted-by":"publisher","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"key":"2026110303165454100_bib26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2015-01-625004","article-title":"Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds","volume":"126","author":"Lagrue","year":"2015","journal-title":"Blood"},{"key":"2026110303165454100_bib27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10143-023-02248-1","article-title":"C-reactive protein levels, the prognostic nutritional index, and the lactate dehydrogenase-to-lymphocyte ratio are important prognostic factors in primary central nervous system lymphoma: a single-center study of 223 patients","volume":"47","author":"Zuo","year":"2023","journal-title":"Neurosurg Rev"},{"key":"2026110303165454100_bib28","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.modpat.2023.100323","article-title":"Genomic profiling of primary diffuse large B-cell lymphoma of the central nervous system suggests novel potential therapeutic targets","volume":"36","author":"Agostinelli","year":"2023","journal-title":"Mod Pathol"},{"key":"2026110303165454100_bib29","doi-asserted-by":"publisher","first-page":"1685271","DOI":"10.3389\/fonc.2025.1685271","article-title":"Relapsed or refractory central nervous system lymphoma successfully treated by glofitamab combined with lenalidomide","volume":"15","author":"Peng","year":"2025","journal-title":"Front Oncol"},{"key":"2026110303165454100_bib30","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/ajh.70342","article-title":"Multicenter real-world analysis of glofitamab in relapsed\/refractory primary CNS lymphoma: clinical activity, CNS penetration, and ctDNA dynamics","volume":"101","author":"Yang","year":"2026","journal-title":"Am J Hematol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0128\/3820809\/bcd-26-0128.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0128\/3829116\/bcd-26-0128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/909\/3844179\/bcd-26-0128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/909\/3844179\/bcd-26-0128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:16:57Z","timestamp":1793693817000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/6\/909\/789637\/Glofitamab-Based-Therapy-for-Relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,11]]},"published-print":{"date-parts":[[2026,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0128","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.34898170","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898161","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898152","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898176","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898155","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898167","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898179","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34898158","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8814751","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]}}}